We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Inhibiting Digestive Enzymes Blocks Malaria Growth

By LabMedica International staff writers
Posted on 10 Feb 2010
A multinational team of parasitologists and molecular biologists used X-ray crystallography to determine the mode of activity of two critical malaria parasite enzymes, which allowed them to suggest a direction for the development of drugs to inactivate them.

The two enzymes, the neutral aminopeptidases, PfA-M1 and PfA-M17 from Plasmodium falciparum, function in regulating the intracellular pool of amino acids required for growth and development of the parasite inside the red blood cell. More...
A previous publication concentrated on PfA-M1, while the current paper, which was published in the January 21, 2010, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS), focused on PfA-M17. While the precise functions of PfA-M1 and PfA-M17 are still speculative, it has been suggested that these enzymes function in the final stages of hemoglobin digestion and degrade the dipeptides produced by the action of various enzymes within the parasite's acidic digestive vacuole. This process is essential for the provision of free amino acids for parasite protein synthesis.

In the current paper, the investigators presented the structure of the hexameric PfA-M17 enzyme, with one and two metal ions bound in the active site. They also determined the structure of PfA-M17 in the complex with the inhibitors bestatin and phosphinic dipeptide analogue. They then compared and contrasted these data with their previously determined structure of PfA-M1 in complex with the same inhibitors and revealed differences in the manner in which the two enzymes receive, bind, and cleave N-terminal amino acid substrates.

The investigators believe that these studies will guide a rational approach toward the development of inhibitors with dual and selective activity for PfA-M17 and PfA-M1. Such reagents should permit key insights into the precise role of each enzyme in the parasite lifecycle and direct the structure-based design of unique classes of antimalarial drugs.

"By blocking the action of these critical parasite enzymes, we have shown that the parasites can no longer survive within the human red blood cell," explained contributing author Dr. John Dalton, professor of parasitology at McGill University (Montreal, QC, Canada).

Related Links:
McGill University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Prefilled Tubes
Prefilled 5.0ml Tubes
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.